There are currently 314 clinical trials in Fort Worth, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including Cook Children's Medical Center, GSK Investigational Site, Cook Children's Medical Center - Fort Worth and UT Southwestern/Simmons Cancer Center-Fort Worth. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
Recruiting
The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/m\^2 or higher and Atherosclerotic Cardiovascular Disease and/or chronic kidney disease. The study will last for about 5 years. Participants will have up to 27 clinic visits with the study doctor.
Gender:
ALL
Ages:
45 years and above
Trial Updated:
05/22/2025
Locations: Diabetes and Thyroid Center of Ft. Worth, Fort Worth, Texas +1 locations
Conditions: Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).
Recruiting
Subjects who completed either OBERON or TITANIA will be offered the opportunity to consent for this Multicentre, Double-blind, Randomised, Placebo controlled, Parallel Group, Phase 3, extension study to evaluate the safety and efficacy of Tozorakimab in adult participants with symptomatic COPD.
Gender:
ALL
Ages:
Between 40 years and 130 years
Trial Updated:
05/22/2025
Locations: Research Site, Fort Worth, Texas
Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy
Recruiting
The primary objective of this study is to evaluate the efficacy of valbenazine versus placebo on improving chorea in pediatric and adult participants who have dyskinesia due to cerebral palsy (DCP) with choreiform movements.
Gender:
ALL
Ages:
Between 6 years and 70 years
Trial Updated:
05/21/2025
Locations: Neurocrine Clinical Site, Fort Worth, Texas
Conditions: Dyskinesia, Cerebral Palsy
Evaluate the Safety and Effectiveness of iSTAR Medical's MINIject™ Implant for Lowering Intraocular Pressure (IOP) in Subjects With Primary Open-angle Glaucoma.
Recruiting
Evaluate the safety and effectiveness of iSTAR Medical's MINIject™ implant for lowering intraocular pressure (IOP) in subjects with primary open-angle glaucoma.
Gender:
ALL
Ages:
46 years and above
Trial Updated:
05/21/2025
Locations: Ophthalmology Associates, Fort Worth, Texas
Conditions: Glaucoma
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Recruiting
This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation in BRCA1, BRCA2, or PALB2. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/21/2025
Locations: UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth, Texas
Conditions: Pancreatic Acinar Cell Carcinoma, Pancreatic Adenosquamous Carcinoma, Pancreatic Squamous Cell Carcinoma, Resectable Pancreatic Acinar Cell Carcinoma, Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Adenosquamous Carcinoma, Resectable Pancreatic Carcinoma
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)
Recruiting
The goal of this clinical study is to find out how the study drug, sacituzumab govitecan (SG) works in participants with endometrial cancer who have received prior treatment with platinum-based chemotherapy and immunotherapy, versus the treatment of physician's choice (TPC). The primary objectives of this study are to evaluate the effect of SG compared to TPC on progression-free survival (PFS) as assessed by blinded independent central review (BICR) and overall survival (OS).
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/21/2025
Locations: Texas Oncology, Fort Worth, Texas
Conditions: Endometrial Cancer
A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer
Recruiting
This study will assess the efficacy, safety, optimal dose and ADA and NAbs development of TRK-950 at two separate dose levels in combination with ramucirumab and paclitaxel (RAM+PTX) as compared with RAM + PTX treatment alone in participants with gastric or gastro-esophageal junction (GEJ) adenocarcinoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/21/2025
Locations: Texas Oncology Fort Worth Cancer Center, Fort Worth, Texas
Conditions: Gastric Adenocarcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer
Recruiting
This phase III trial compares the effect of sentinel lymph node mapping to standard lymph node dissection in reducing the risk of swelling in the legs (lymphedema) in patients undergoing a hysterectomy for stage I endometrial cancer. Standard lymph node dissection removes lymph nodes around the uterus during a hysterectomy to look for spread of cancer from the uterus to nearby lymph nodes. Sentinel lymph node mapping uses a special dye and camera to look for cancer that may have spread to nearby... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/20/2025
Locations: UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth, Texas
Conditions: Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial
Recruiting
This phase II trial compares the effect of atezolizumab in combination with usual treatment with cabozantinib to cabozantinib alone in patients with papillary renal cell carcinoma that has spread from where it first started (primary site) to other places in the body (metastatic). Papillary renal cell carcinoma (PRCC) is a type of kidney cancer that forms in the lining of the tiny tubes in the kidney that return filtered substances that the body needs back to the blood and remove extra fluid and... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2025
Locations: UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth, Texas
Conditions: Metastatic Papillary Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
Recruiting
The main purpose of this study is to evaluate the long-term efficacy of mirikizumab in pediatric participants with ulcerative colitis (UC) or Crohn's disease (CD). The study will last about 172 weeks and may include up to 44 visits.
Gender:
ALL
Ages:
Between 2 years and 19 years
Trial Updated:
05/20/2025
Locations: Cook Children's Medical Center, Fort Worth, Texas
Conditions: Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
Recruiting
The main purpose of the master is to help the research sites and sponsor carry out several clinical trials more efficiently by providing a common research protocol. Individual clinical trials under this master protocol define drug/disease-specific research goals and activities to test them. New studies will be added as new drugs emerge against different cancers. Participation in the trial will depend on how long the benefit lasts.
Gender:
ALL
Ages:
Between 1 year and 39 years
Trial Updated:
05/20/2025
Locations: Cook Children's Hospital, Fort Worth, Texas
Conditions: Neoplasms, Child, Adolescent
A Longitudinal Observational Study of the Natural History and Management of Patients With HCC
Recruiting
TARGET-HCC is a longitudinal, observational study of patients being managed for HCC in usual clinical practice. TARGET-HCC will create a research registry of participants with HCC within academic and community real-world practices in order to assess the safety and effectiveness of the entire spectrum of current and future therapies across diverse populations.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2025
Locations: Baylor Scott & White All Saints, Fort Worth, Texas
Conditions: Hepatocellular Cancer